| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9266281 | Immunology Letters | 2005 | 6 Pages |
Abstract
Thymidylate synthase (TYMS), the critical enzyme for DNA synthesis and a target for chemotherapy, was recently characterized as an oncogene and a potential target for specific immunotherapy. Here we report TYMS-specific antibody response in a fraction of colon cancer patients. Humoral immune response to TYMS is induced by chemotherapy using TYMS inhibitors, such as 5-fluorouracil (5-FU), and may be associated with tumor burden. Therefore, TYMS may serve as a useful serological biomarker for monitoring the course of disease and treatment in cancer patients.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Yuriy V. Shebzukhov, Ekaterina P. Koroleva, Svetlana V. Khlgatian, Maria A. Lagarkova, Andrey A. Meshcheryakov, Mikhail R. Lichinitser, Julia Karbach, Elke Jager, Dmitry V. Kuprash, Sergei A. Nedospasov,